IMBiologics

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

imbiologics.com

Country

South Korea

Exchange

KOSDAQ

Founded 2020

IMBiologics Corp., a biotechnology company develops immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechanisms mediating Th1/Th17 immune responses.

Its portfolio also includes IMB-102, IMB-201, an antibody-drug conjugate that targets HLA-G, a tumor-specific antigen, and IMB-402, a concept anticancer vaccine bispecific antibody that utilizes the ePENDY (IgM-Agonist) modality to activate cancer cell-specific T cells. Founded in 2020, IMBiologics is based in Suwon-si, South Korea.

Key Stats

52-Week Range

₩13190.00₩104000.00

BetaN/A

Trailing P/EN/A

Forward P/EN/A

Trailing EPSN/A

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.